ASTRAZENECA PLC (AZN) — SEC Filings

Latest SEC filings for ASTRAZENECA PLC (AZN), explained in plain English.

Sentiment Overview: 19 bullish, 31 neutral

Recent Filings (50)

• AstraZeneca's Liver Cancer Drug Combo Shows Improved PFS — 6-K · 2026-04-02T09:27:28-04:00 [bullish] Risk: low
  On April 2, 2026, AstraZeneca PLC filed a Form 6-K reporting that their IMFINZI and IMJUDO combination therapy has shown improved progression-free survival (PFS
• AstraZeneca PLC Files 6-K on Voting Rights — 6-K · 2026-04-01T10:30:32-04:00 [neutral] Risk: low
  On April 1, 2026, AstraZeneca PLC filed a Form 6-K with the SEC, reporting its total voting rights and the admission of shares. The filing provides details on t
• AstraZeneca's IMFINZI Shows Positive Phase III Lung Cancer Results — 6-K · 2026-03-31T07:48:12-04:00 [bullish] Risk: low
  AstraZeneca PLC announced on March 31, 2026, that its IMFINZI (durvalumab) in combination with chemotherapy demonstrated positive results in the Phase III ALTA-
• 6-K Filing — 6-K · 2025-12-22T00:00:00.000Z [neutral]
• 6-K Filing — 6-K · 2025-12-19T00:00:00.000Z [neutral]
• Enhertu Gets US Approval for 1st-Line HER2+ Breast Cancer — 6-K · 2025-12-16T00:00:00.000Z [bullish] Risk: low
  AstraZeneca PLC announced on December 16, 2025, that its drug Enhertu has received US approval for first-line treatment of HER2-positive metastatic breast cance
• AstraZeneca PLC Files 6-K Report — 6-K · 2025-12-04T00:00:00.000Z [neutral] Risk: low
  AstraZeneca PLC filed a Form 6-K on December 4, 2025, reporting its status as a foreign issuer. The filing indicates that AstraZeneca is submitting its reports
• AstraZeneca PLC Files 6-K Report — 6-K · 2025-12-01T00:00:00.000Z [neutral] Risk: low
  AstraZeneca PLC filed a Form 6-K on December 1, 2025, reporting as a foreign issuer. The filing indicates that the company is submitting its report under the 19
• AstraZeneca's Imfinzi Approved for Early Gastric Cancer in US — 6-K · 2025-11-26T00:00:00.000Z [bullish] Risk: low
  AstraZeneca PLC announced on November 26, 2025, that its drug Imfinzi has received US approval for the treatment of early-stage gastric cancer. This approval ma
• AstraZeneca Announces Maryland Manufacturing Investment — 6-K · 2025-11-24T00:00:00.000Z [neutral] Risk: low
  AstraZeneca PLC announced a manufacturing investment in Maryland, USA, on November 24, 2025. The company, headquartered in Cambridge, UK, is filing a Form 6-K r
• AstraZeneca's Koselugo Approved in US — 6-K · 2025-11-20T00:00:00.000Z [bullish] Risk: low
  AstraZeneca PLC announced on November 20, 2025, that Koselugo (selumeticinib) has been approved in the US. This marks a significant milestone for the company's
• 6-K Filing — 6-K · 2025-11-17T00:00:00.000Z [neutral]
• 6-K Filing — 6-K · 2025-11-14T00:00:00.000Z [neutral]
• AstraZeneca PLC Files Director Shareholding Report — 6-K · 2025-11-10T00:00:00.000Z [neutral] Risk: low
  AstraZeneca PLC filed a Form 6-K on November 10, 2025, reporting its shareholdings for Directors and Persons Disclosing Managerial Responsibilities (PDMRs). Thi
• AstraZeneca PLC Files 9M and Q3 2025 Results — 6-K · 2025-11-06T00:00:00.000Z [neutral] Risk: low
  AstraZeneca PLC filed a Form 6-K on November 6, 2025, reporting its 9-month and Q3 2025 results. The filing is a report of a foreign issuer and indicates that A
• 6-K Filing — 6-K · 2025-11-03T00:00:00.000Z [neutral]
• AstraZeneca PLC Files November 2025 6-K Report — 6-K · 2025-11-03T00:00:00.000Z [neutral] Risk: low
  AstraZeneca PLC filed a Form 6-K on November 3, 2025, reporting as a foreign issuer. The filing is for the month of November 2025 and indicates the company file
• AstraZeneca's Koselugo Approved in EU for NF1 — 6-K · 2025-10-28T00:00:00.000Z [bullish] Risk: low
  AstraZeneca PLC announced on October 28, 2025, that Koselugo (selumeticinib) has received approval in the European Union. This approval is for the treatment of
• Tezspire Approved in EU for CRSwNP — 6-K · 2025-10-22T00:00:00.000Z [bullish] Risk: low
  AstraZeneca PLC announced on October 22, 2025, that Tezspire has received European Union approval for the treatment of Chronic Rhinosinusitis with Nasal Polyps
• AstraZeneca's SAPHNELO gets positive EU opinion — 6-K · 2025-10-20T00:00:00.000Z [bullish] Risk: low
  AstraZeneca PLC announced on October 20, 2025, that it received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Hum
• AstraZeneca Agrees to Lower US Medicine Prices — 6-K · 2025-10-14T00:00:00.000Z [neutral] Risk: medium
  AstraZeneca PLC filed a Form 6-K on October 14, 2025, reporting an agreement with the US Government to lower medicine prices. This filing is made pursuant to Ru
• AstraZeneca's BAXDROSTAT Trial Meets Primary Endpoint — 6-K · 2025-10-07T00:00:00.000Z [bullish] Risk: low
  AstraZeneca PLC announced on October 7, 2025, that its BAXDROSTAT Phase 3 trial, BAX24, met its primary endpoint. The trial evaluated BAXDROSTAT for the treatme
• AstraZeneca's Dato-DXd Shows Improved Survival in Breast Cancer Trial — 6-K · 2025-10-06T00:00:00.000Z [bullish] Risk: medium
  AstraZeneca PLC filed a Form 6-K on October 6, 2025, reporting on the TROPION-Breast02 trial. The filing indicates improved overall survival (OS) and progressio
• AstraZeneca PLC Files 6-K Report — 6-K · 2025-10-01T00:00:00.000Z [neutral] Risk: low
  AstraZeneca PLC filed a Form 6-K on October 1, 2025, reporting as a foreign issuer. The filing indicates that AstraZeneca is submitting its reports under Form 2
• AstraZeneca Harmonizes Listing Structure — 6-K · 2025-09-29T00:00:00.000Z [neutral] Risk: low
  AstraZeneca PLC announced on September 29, 2025, that it is harmonizing its listing structure. This move aims to simplify its corporate structure and enhance it
• AstraZeneca PLC Files 6-K Report — 6-K · 2025-09-29T00:00:00.000Z [neutral] Risk: low
  AstraZeneca PLC filed a Form 6-K on September 29, 2025, to report information as a foreign private issuer. The filing indicates that AstraZeneca is required to
• AstraZeneca PLC Files 6-K Shareholding Report — 6-K · 2025-09-25T00:00:00.000Z [neutral] Risk: low
  AstraZeneca PLC filed a Form 6-K on September 25, 2025, reporting its shareholding information as required for foreign issuers. The filing indicates the company
• AstraZeneca's Tezspire gets EU nod for nasal polyps — 6-K · 2025-09-22T00:00:00.000Z [bullish] Risk: low
  AstraZeneca PLC announced on September 22, 2025, that their drug Tezspire has been recommended for approval in the European Union for the treatment of severe un
• AstraZeneca's RESOLUTE Trial Meets Primary Endpoint — 6-K · 2025-09-17T00:00:00.000Z [bullish] Risk: medium
  AstraZeneca PLC announced an update on its RESOLUTE Phase III trial for its investigational medicine, Zynyz (retifanlimab-dlwr), in combination with chemotherap
• AstraZeneca Files Routine 6-K Report — 6-K · 2025-09-02T00:00:00.000Z [neutral] Risk: low
  AstraZeneca PLC filed a Form 6-K on September 2, 2025, reporting for the month of September 2025. The company, registered under SEC file number 001-11960, is a
• AstraZeneca PLC Files 6-K Report — 6-K · 2025-08-28T00:00:00.000Z [neutral] Risk: low
  AstraZeneca PLC filed a Form 6-K on August 28, 2025, reporting its status as a foreign issuer. The company, formerly known as ZENECA GROUP PLC until April 22, 1
• AstraZeneca PLC Files Form 6-K — 6-K · 2025-08-26T00:00:00.000Z [neutral] Risk: low
  AstraZeneca PLC filed a Form 6-K on August 26, 2025, reporting its status as a foreign issuer. The filing confirms AstraZeneca PLC's principal executive offices
• AstraZeneca PLC Files Form 6-K — 6-K · 2025-08-21T00:00:00.000Z [neutral] Risk: low
  AstraZeneca PLC filed a Form 6-K on August 21, 2025, reporting its status as a foreign issuer. The filing indicates that AstraZeneca is submitting its reports u
• AstraZeneca PLC Files 6-K for Director Shareholding — 6-K · 2025-08-18T00:00:00.000Z [neutral] Risk: low
  AstraZeneca PLC filed a Form 6-K on August 18, 2025, reporting its shareholding information for Directors and PDMRs (Persons Discharging Managerial Responsibili
• AstraZeneca PLC Files Form 6-K — 6-K · 2025-08-15T00:00:00.000Z [neutral] Risk: low
  AstraZeneca PLC filed a Form 6-K on August 15, 2025, reporting its status as a foreign issuer. The filing confirms that AstraZeneca is submitting its annual rep
• AstraZeneca PLC Files 6-K Report — 6-K · 2025-08-12T00:00:00.000Z [neutral] Risk: low
  AstraZeneca PLC filed a Form 6-K on August 12, 2025, reporting its status as a foreign issuer. The filing confirms that AstraZeneca is submitting its annual rep
• AstraZeneca PLC Files Form 6-K for August 2025 — 6-K · 2025-08-01T00:00:00.000Z [neutral] Risk: low
  AstraZeneca PLC filed a Form 6-K on August 1, 2025, reporting for the month of August 2025. The company, previously known as ZENECA GROUP PLC until April 22, 19
• AstraZeneca PLC Files 6-K for Q2 2025 — 6-K · 2025-07-29T00:00:00.000Z [neutral] Risk: low
  AstraZeneca PLC filed a 6-K report on July 29, 2025, for the period ending June 30, 2025. The filing includes information related to various product segments su
• AstraZeneca's Gefulimab Nanobody Hits Phase III Endpoints — 6-K · 2025-07-24T00:00:00.000Z [bullish] Risk: low
  AstraZeneca PLC announced on July 24, 2025, that its Gefulimab nanobody met the primary endpoints in a Phase III trial. The trial evaluated Gefulilimab in combi
• AstraZeneca to Invest $50 Billion in US — 6-K · 2025-07-22T00:00:00.000Z [bullish] Risk: low
  AstraZeneca PLC announced plans to invest $50 billion in the United States over the next 10 years, focusing on research and development, manufacturing, and expa
• AstraZeneca Updates on AL Amyloidosis Drug Anselamimab — 6-K · 2025-07-16T00:00:00.000Z [neutral] Risk: low
  AstraZeneca PLC announced an update on its investigational drug anselamimab for AL amyloidosis on July 16, 2025. The company is providing this information as pa
• AstraZeneca's BAXdrostat Meets Primary Endpoint in Phase III Trial — 6-K · 2025-07-14T00:00:00.000Z [bullish] Risk: low
  AstraZeneca PLC announced on July 14, 2025, that its investigational medicine BAXdrostat met the primary endpoint in the BAXHTN Phase III trial. The trial evalu
• AstraZeneca's Imfinzi gets EU approval for Stage III NSCLC — 6-K · 2025-07-07T00:00:00.000Z [bullish] Risk: low
  AstraZeneca PLC announced on July 7, 2025, that its Imfinzi drug has received approval in the European Union for the treatment of adult patients with unresectab
• AstraZeneca PLC Files July 2025 6-K Report — 6-K · 2025-07-01T00:00:00.000Z [neutral] Risk: low
  AstraZeneca PLC filed a Form 6-K on July 1, 2025, reporting for the month of July 2025. The filing indicates that AstraZeneca is a foreign issuer and files annu
• AstraZeneca's Datroway Approved in US for Lung Cancer — 6-K · 2025-06-24T00:00:00.000Z [bullish] Risk: low
  AstraZeneca PLC announced on June 24, 2025, that its drug Datopotamab deruxtecan (Datroway) has been approved in the US for the treatment of adult patients with
• AstraZeneca Collaborates with CSPC — 6-K · 2025-06-13T00:00:00.000Z [neutral] Risk: low
  AstraZeneca PLC announced on June 13, 2025, that it has entered into a collaboration with CSPC. This partnership aims to advance the development of innovative m
• AstraZeneca PLC Files 6-K on Director Shareholdings — 6-K · 2025-06-12T00:00:00.000Z [neutral] Risk: low
  AstraZeneca PLC filed a Form 6-K on June 12, 2025, reporting its shareholding information for Directors and Persons Discharging Managerial Responsibility (PDMRs
• EU Approves AstraZeneca's CALQUENCE for First-Line CLL — 6-K · 2025-06-06T00:00:00.000Z [bullish] Risk: low
  AstraZeneca PLC announced on June 6, 2025, that the European Commission has approved a fixed-duration regimen of CALQUENCE (acalabrutinib) for the first-line tr
• AstraZeneca PLC Files June 2025 6-K Report — 6-K · 2025-06-02T00:00:00.000Z [neutral] Risk: low
  AstraZeneca PLC filed a Form 6-K on June 2, 2025, reporting for the month of June 2025. The filing indicates AstraZeneca is a foreign issuer and files annual re
• AstraZeneca's Imfinzi gets EU nod for biliary tract cancer — 6-K · 2025-05-27T00:00:00.000Z [bullish] Risk: low
  AstraZeneca PLC announced on May 27, 2025, that its Imfinzi (durvalumab) has received a positive recommendation from the European Medicines Agency's Committee f